Clinical use of aclidinium in patients with COPD

References

• Centers for Disease Control and Prevention (CDC)Chronic obstructive pulmonary disease among adults – United States, 2001MMWR e Mortal Wkly Rep20126146938943
   PubMedGoogle Scholar
• Global initiative for Chronic Obstructive Lung Disease (GOLD)Global Strategy for the Diagnosis, Management and Prevention of COPD (GOLD) 2013 Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2014_Jan23.pdfAccessed January 28, 2014
   Google Scholar
• WilliamsDMBourdetSVChronic obstructive pulmonary diseaseDiPiroJTTalbertRLYeeGCMatzeGRWellsBGPoseyMLPharmacotherapy: A Pathophysiologic Approach8th edNew York, NYMcGraw-Hill2011471496 Available from: http://www.accesspharmacy.com/content.aspx?aID=7975888Accessed November 15, 2013
   Google Scholar
• ChapmanKRManninoDMSorianoJBEpidemiology and costs of chronic obstructive pulmonary diseaseEur Respir J200627118820716387952
   PubMed Web of Science ®Google Scholar
• Tudorza™ Pressair™ (aclidinium bromide inhalation powder) [product information]St Louis, MOForest Pharmaceuticals, Inc.2012 Available from: http://www.frx.com/pi/tudorza_pi.pdfAccessed on March 6, 2014
   Google Scholar
• BelmonteKCholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary diseaseProc Am Thorac Soc20052429730416267352
   PubMedGoogle Scholar
• GavaldàAMiralpeixMRamosICharacterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profileJ Pharmacol Exp Ther2009331274075119710368
   PubMed Web of Science ®Google Scholar
• PratMFernándezDBuilMADiscovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (aclidinium bromide)J Med Chem200952165076509219653626
   PubMed Web of Science ®Google Scholar
• LasseterKDilzerSJansatJMGarcia GilECaractaCFOrtizSSafety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteersPulm Pharmacol Ther201225219319922366196
   PubMed Web of Science ®Google Scholar
• JansatJMLamarcaRGilEGFerrerPSafety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjectsInt J Clin Pharmacol Ther200947746046819640353
   PubMed Web of Science ®Google Scholar
• FuhrRMagnussenHSaremKEfficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPDChest2012141374575221903737
   PubMed Web of Science ®Google Scholar
• Spiriva^® HandiHaler^® (tiotropium bromide inhalation powder) [product information]Ridgefield, CTBoehringer Ingelheim Pharmaceuticals, Inc.2013
   Google Scholar
• SchmidKPascualSGilEGOrtizSJansatJMPharmacokinetics and safety of aclidinium bromide, a muscarinic antagonist, in adults with normal or impaired renal function: A phase I, open-label, single-dose clinical trialClin Ther201032101798181221194604
   PubMed Web of Science ®Google Scholar
• JoosGFSchelfhoutVJPauwelsRABronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patientsRespir Med2010104686587220044242
   PubMed Web of Science ®Google Scholar
• ChanezPBurgePSDahlRAclidinium bromide provides long-acting bronchodilation in patients with COPDPulm Pharmacol Ther2010231152119683590
   PubMed Web of Science ®Google Scholar
• VestboJVogelmeierCCreemersJFalquesMRiberaAGilEGOnset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPDCOPD20107533133620854047
   PubMedGoogle Scholar
• JonesPWRennardSIAgustiAEfficacy and safety of once-daily aclidinium in chronic obstructive pulmonary diseaseRespir Res2011125521518460
   PubMed Web of Science ®Google Scholar
• SinghDMagnussenHKirstenAA randomised, placebo- and active-controlled dose-finding study of aclidinium bromide administered twice a day in COPD patientsPulm Pharmacol Ther201225324825322497752
   PubMed Web of Science ®Google Scholar
• JonesPWSinghDBatemanEDEfficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN studyEur Respir J201240483083622441743
   PubMed Web of Science ®Google Scholar
• KerwinEMD’UrzoADGelbAFLakkisHGarcia GilECaractaCFACCORD I study InvestigatorsEfficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I)COPD2012929010122320148
   PubMedGoogle Scholar
• D’UrzoAKerwinERennardSHeTGilEGCaractaCOne-year extension study of ACCORD COPD I: safety and efficacy of two doses of twice-daily aclidinium bromide in patients with COPDCOPD201310450051023679347
   PubMedGoogle Scholar
• RennardSIScanlonPDFergusonGTACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patientsClin Drug Investig20133312893904
   PubMed Web of Science ®Google Scholar
• BeierJKirstenAMrózREfficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb studyCOPD201310451152223819698
   PubMedGoogle Scholar
• GelbAFTashkinDPMakeBJZhongXGarcia GilECaractaCLAS-MD-35 study InvestigatorsLong-term safety and efficacy of twice-daily aclidinium bromide in patients with COPDRespir Med2013107121957196523916502
   PubMed Web of Science ®Google Scholar
• DonohueJFMinimal clinically important differences in COPD lung functionCOPD20052111112417136971
   PubMedGoogle Scholar
• JonesPWSt George’s Respiratory Questionnaire: MCIDCOPD200521757917136966
   PubMedGoogle Scholar
• MahlerDAWItekTJJrThe MCID of the transition dyspnea index is a total score of one unitCOPD20052111112417136971
   PubMedGoogle Scholar
• SinghSLokeYKFurbergCDInhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysisJAMA2008300121439145018812535
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBSennSUPLIFT Study InvestigatorsA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
   PubMed Web of Science ®Google Scholar
• MicheleTMPinheiroSIyasuSThe safety of tiotropium – the FDA’s conclusionsN Engl J Med2010363121097109920843240
   PubMed Web of Science ®Google Scholar
• LasseterKCAubetsJChuecosFGilEGAclidinium bromide, a long-acting antimuscarinic, does not affect QT interval in healthy subjectsJ Clin Pharmacol201151692393220959525
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO)Adherence to Long-term Therapies Evidence for ActionGenevaWHO2003 Available from: http://www.who.int/chp/knowledge/publications/adherence_report/en/Accessed January 29, 2014
   Google Scholar
• BourbeauJBartlettSJPatient adherence in COPDThorax200863983183818728206
   PubMed Web of Science ®Google Scholar
• VestboJAndersonJACalverleyPMAdherence to inhaled therapy, mortality and hospital admission in COPDThorax2009641193994319703830
   PubMed Web of Science ®Google Scholar
• Van der PalenJGinkoTKrokerAPreference, satisfaction and errors with two dry powder inhalers in patients with COPDExpert Opin Drug Deliv20131081023103123745954
   PubMed Web of Science ®Google Scholar